Myeloproliferative Neoplasms News

Hypomethylating agents azacitidine and decitabine appeared associated with a 5-year OS probability rate of 4% among patients with myelodysplastic syndrome with refractory anemia with excess blasts who did not undergo allogeneic stem cell transplantation, according to a study published in Blood.

Alexis A. Thompson, MD, MPH, took over as ASH president in January.

Patients with hematologic malignancies received more aggressive care at the end of life than patients with solid tumors, according to results of a retrospective cohort study.

The JAK2 inhibitor pacritinib appeared more effective than best available therapies for reducing splenomegaly and symptoms among patients with myelofibrosis and thrombocytopenia, according to study results published in JAMA Oncology.

SALT LAKE CITY — Ruxolitinib treatment prior to allogeneic hematopoietic stem cell transplant appeared safe and aided in the prevention of cytokine release syndrome among patients with myelofibrosis, according to results of a phase 2 prospective study presented at the BMT Tandem Meetings.

HemOnc Today and Healio.com will provide live coverage from BMT Tandem Meetings, scheduled for Feb. 21-25 in Salt Lake City.

ATLANTA — Incidence of Wernicke’s encephalopathy appeared quite low among patients with myeloproliferative neoplasms treated with fedratinib, according to study results presented at ASH Annual Meeting and Exposition.

ATLANTA — Idasanutlin demonstrated clinical activity among patients with refractory polycythemia vera, according to study results presented at ASH Annual Meeting and Exposition.

The FDA expanded clearance of the ipsogen JAK2 RCQ PCR Kit for supplemental use in the diagnosis of all myeloproliferative neoplasms, according to a company press release.

The rate of arterial and venous thrombosis was significant in patients with myeloproliferative neoplasms, according to research published in Annals of Internal Medicine.